Matthias Theobald

This paper introduces a fine-tuned chimeric switch receptor (CSR) that enhances TCR/CAR T cell metabolic fitness and antitumor efficacy by optimizing signaling from the TIGIT domain.

This paper shows menin inhibitors increase CLEC12A expression in AML, making it more responsive to CLEC12A-targeted CAR T cells, improving treatment outcomes.

This study shows that inhibiting the DNMT/G9a complex targets specific epigenetic vulnerabilities in AML, inducing an IFN response and improving therapeutic outcomes.